{"id":"https://openalex.org/W2270318974","doi":"https://doi.org/10.1016/s0022-3565(25)20957-0","title":"Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay.","display_name":"Agonist potency at the cloned human beta-3 adrenoceptor depends on receptor expression level and nature of assay.","publication_year":1996,"publication_date":"1996-10-01","ids":{"openalex":"https://openalex.org/W2270318974","doi":"https://doi.org/10.1016/s0022-3565(25)20957-0","mag":"2270318974","pmid":"https://pubmed.ncbi.nlm.nih.gov/8858996"},"language":"en","primary_location":{"id":"doi:10.1016/s0022-3565(25)20957-0","doi":"https://doi.org/10.1016/s0022-3565(25)20957-0","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0022-3565(25)20957-0","pdf_url":null,"source":{"id":"https://openalex.org/S102125482","display_name":"Journal of Pharmacology and Experimental Therapeutics","issn_l":"0022-3565","issn":["0022-3565","1521-0103"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Pharmacology and Experimental Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111855634","display_name":"Shelagh Wilson","orcid":"https://orcid.org/0000-0002-7001-1851","observed_orcids":["https://orcid.org/0000-0002-7001-1851"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S Wilson","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113716835","display_name":"Jonathan K. Chambers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J K Chambers","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003831256","display_name":"J E Park","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J E Park","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068711489","display_name":"Andreas G. Ladurner","orcid":"https://orcid.org/0000-0003-3835-232X","observed_orcids":["https://orcid.org/0000-0003-3835-232X"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A Ladurner","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008620471","display_name":"David Cronk","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D W Cronk","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028380241","display_name":"Conrad G. Chapman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C G Chapman","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040248064","display_name":"Howard Kallender","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"H Kallender","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M J Browne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M J Browne","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":null,"display_name":"G J Murphy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"G J Murphy","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060131441","display_name":"Paul William Young","orcid":"https://orcid.org/0000-0002-1307-0249","observed_orcids":["https://orcid.org/0000-0002-1307-0249"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P W Young","raw_affiliation_strings":["Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biotechnology, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Harlow, Essex, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I188950975"],"apc_list":{"value":3750,"currency":"USD","value_usd":3750},"apc_paid":null,"fwci":1.4852,"has_fulltext":false,"cited_by_count":58,"citation_normalized_percentile":{"value":0.8123084,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"279","issue":"1","first_page":"214","last_page":"221"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/beta-3-adrenoceptor","display_name":"beta-3 adrenoceptor","score":0.9800000190734863},{"id":"https://openalex.org/keywords/agonist-potency","display_name":"agonist potency","score":0.8899999856948853},{"id":"https://openalex.org/keywords/receptor-expression-levels","display_name":"receptor expression levels","score":0.8980000019073486},{"id":"https://openalex.org/keywords/intrinsic-efficacy","display_name":"intrinsic efficacy","score":0.6710000038146973},{"id":"https://openalex.org/keywords/brl-37344","display_name":"BRL37344","score":0.9710000157356262},{"id":"https://openalex.org/keywords/catecholamines","display_name":"catecholamines","score":0.8180000185966492},{"id":"https://openalex.org/keywords/norepinephrine","display_name":"norepinephrine","score":0.9850000143051147},{"id":"https://openalex.org/keywords/cgp-12177","display_name":"CGP 12177","score":0.9369999766349792},{"id":"https://openalex.org/keywords/aryloxypropanolamines","display_name":"aryloxypropanolamines","score":0.9459999799728394},{"id":"https://openalex.org/keywords/adenylyl-cyclase-activation","display_name":"adenylate cyclase activation","score":0.8539999723434448},{"id":"https://openalex.org/keywords/camp-accumulation","display_name":"cAMP accumulation","score":0.8949999809265137},{"id":"https://openalex.org/keywords/operations-analysis","display_name":"operational analysis","score":0.4180000126361847}],"concepts":[{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.9004075527191162},{"id":"https://openalex.org/C175656101","wikidata":"https://www.wikidata.org/wiki/Q56646","display_name":"Chinese hamster ovary cell","level":3,"score":0.8320740461349487},{"id":"https://openalex.org/C38533456","wikidata":"https://www.wikidata.org/wiki/Q1671589","display_name":"Intrinsic activity","level":4,"score":0.6889677047729492},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.6833957433700562},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.6188470125198364},{"id":"https://openalex.org/C2779178603","wikidata":"https://www.wikidata.org/wiki/Q356257","display_name":"Adenylyl cyclase","level":3,"score":0.5908753275871277},{"id":"https://openalex.org/C58732023","wikidata":"https://www.wikidata.org/wiki/Q770260","display_name":"Partial agonist","level":4,"score":0.5726618766784668},{"id":"https://openalex.org/C2776174256","wikidata":"https://www.wikidata.org/wiki/Q830842","display_name":"BETA (programming language)","level":2,"score":0.5018117427825928},{"id":"https://openalex.org/C2776090920","wikidata":"https://www.wikidata.org/wiki/Q415550","display_name":"Isoprenaline","level":3,"score":0.49782824516296387},{"id":"https://openalex.org/C15324608","wikidata":"https://www.wikidata.org/wiki/Q14916359","display_name":"Beta-1 adrenergic receptor","level":3,"score":0.4480663537979126},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4384270906448364},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4203205108642578},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3819250762462616},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.37630972266197205},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.370278537273407},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3666641414165497},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3194032907485962},{"id":"https://openalex.org/C24998067","wikidata":"https://www.wikidata.org/wiki/Q4114622","display_name":"Stimulation","level":2,"score":0.117327481508255},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.06901746988296509},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000242","descriptor_name":"Cyclic AMP","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000262","descriptor_name":"Adenylyl Cyclases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000318","descriptor_name":"Adrenergic beta-Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006224","descriptor_name":"Cricetinae","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011412","descriptor_name":"Propanolamines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011943","descriptor_name":"Receptors, Adrenergic, beta","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D011943","descriptor_name":"Receptors, Adrenergic, beta","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016466","descriptor_name":"CHO Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D022702","descriptor_name":"Receptors, Adrenergic, beta-3","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1016/s0022-3565(25)20957-0","doi":"https://doi.org/10.1016/s0022-3565(25)20957-0","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0022-3565(25)20957-0","pdf_url":null,"source":{"id":"https://openalex.org/S102125482","display_name":"Journal of Pharmacology and Experimental Therapeutics","issn_l":"0022-3565","issn":["0022-3565","1521-0103"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Pharmacology and Experimental Therapeutics","raw_type":"journal-article"},{"id":"pmid:8858996","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8858996","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of pharmacology and experimental therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1014.5540","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1014.5540","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://jpet.aspetjournals.org/content/279/1/214.full.pdf","raw_type":"text"},{"id":"mag:2270318974","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8858996","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":6,"referenced_works":["https://openalex.org/W1520083061","https://openalex.org/W1603981767","https://openalex.org/W1946715106","https://openalex.org/W1966603679","https://openalex.org/W2061513165","https://openalex.org/W2074631079"],"related_works":["https://openalex.org/W1968136804","https://openalex.org/W1978625892","https://openalex.org/W938033972","https://openalex.org/W2044732368","https://openalex.org/W1919944459","https://openalex.org/W1548131418","https://openalex.org/W1946645080","https://openalex.org/W2219941561","https://openalex.org/W1922812725","https://openalex.org/W1972226602"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}